<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278460</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000462116</org_study_id>
    <secondary_id>CCCWFU-62199</secondary_id>
    <secondary_id>AVENTIS-CCCWFU-62199</secondary_id>
    <secondary_id>AG-CCCWFU-62199</secondary_id>
    <secondary_id>CCCWFU-BG99-322</secondary_id>
    <nct_id>NCT00278460</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel&#xD;
      works in treating patients with recurrent stage III or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate of patients with recurrent stage IIIB and IV non-small cell&#xD;
           lung cancer treated with gemcitabine hydrochloride and docetaxel.&#xD;
&#xD;
        -  Determine the overall and progression-free survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive gemcitabine hydrochloride IV over 30 minutes followed by docetaxel&#xD;
      IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 51 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient response rate to weekly taxotere and gemcitabine</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate toxicity of weekly Taxotere and Gemcitabine</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">49</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IIIB or IV non-small cell lung cancer, including any of&#xD;
             the following types:&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Adenocarcinoma, including bronchoalveolar cell adenocarcinoma&#xD;
&#xD;
               -  Large cell anaplastic carcinoma, including giant and clear cell carcinomas&#xD;
&#xD;
          -  Histologic or cytologic documentation of recurrence is required&#xD;
&#xD;
          -  Measurable or evaluable disease, defined as any mass reproducibly measurable in 2&#xD;
             perpendicular diameters by physical examination or imaging&#xD;
&#xD;
               -  The following lesions are not considered measurable or evaluable:&#xD;
&#xD;
                    -  Bone disease only&#xD;
&#xD;
                    -  Pleural or pericardial effusions&#xD;
&#xD;
                    -  Previously irradiated lesions, unless subsequent progression is documented&#xD;
&#xD;
          -  CNS metastases allowed provided the patient undergoes at least 2 weeks of radiotherapy&#xD;
             prior to study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  CALGB performance status ≤ 1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Granulocyte count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 2 times normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT and/or SGPT ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase ≤&#xD;
             1.5 times ULN OR&#xD;
&#xD;
          -  Alkaline phosphatase 4 times ULN and SGOT and/or SGPT normal&#xD;
&#xD;
          -  Ejection fraction normal by ECHO or MUGA&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  No psychiatric illness that would preclude study compliance&#xD;
&#xD;
          -  No serious medical or psychiatric illness that would preclude giving informed consent&#xD;
             or limit survival to &lt; 3 months&#xD;
&#xD;
          -  No active uncontrolled bacterial, fungal, or viral infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated carcinoma in&#xD;
             situ of the cervix or breast, basal cell or squamous carcinoma of the skin, or other&#xD;
             surgically resected non-recurrent primary tumor not treated with adjuvant radiotherapy&#xD;
             or chemotherapy&#xD;
&#xD;
          -  No pre-existing peripheral neuropathy ≥ grade 2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery and recovered from acute effects&#xD;
&#xD;
          -  At least 2 weeks since prior palliative radiotherapy and recovered from acute toxic&#xD;
             effects&#xD;
&#xD;
               -  Any persistent toxicity (e.g., alopecia or hyperpigmentation) not associated with&#xD;
                  clinical morbidity allowed&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No concurrent cranial or thoracic radiation therapy&#xD;
&#xD;
          -  No concurrent cytotoxic or hormonal therapy&#xD;
&#xD;
          -  Concurrent palliative radiotherapy allowed for relief of localized pain and&#xD;
             obstruction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonius A. Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

